Sleeping beauty transposed pbl

Sleeping beauty transposed pbl is an investigational cell therapy that utilizes the Sleeping Beauty (SB) transposon system to genetically engineer autologous peripheral blood lymphocytes (PBLs), typically T cells, for cancer immunotherapy. The SB system is a synthetic DNA transposon platform designed to introduce specific DNA sequences into the genome of vertebrate cells via a "cut-and-paste" mechanism mediated by the SB transposase enzyme. In this context, patient-derived T cells are engineered ex vivo using the SB system to express tumor-specific receptors—such as chimeric antigen receptors (CARs) or T-cell receptors (TCRs)—targeting mutated neoantigens in cancer. These modified T cells are then expanded and reinfused into patients with metastatic cancers, including small cell neuroendocrine carcinoma of the bladder, breast carcinoma, and cervical carcinoma[1][2][3][5]. The approach aims to enhance anti-tumor immune responses by redirecting patient immune cells against malignant targets. Developed by the National Cancer Institute, this therapy has been investigated in clinical trials for various metastatic cancers.

Other names

Sleeping Beauty Transposed PBL(NCI)